Skip to main content

NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $200.75
  • Forecasted Upside: 2.73 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$195.42
▲ +1.53 (0.79%)
1 month | 3 months | 12 months
Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$200.75
▲ +2.73% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $200.75, with a high forecast of $235.00 and a low forecast of $144.00. The average price target represents a 2.73% upside from the last price of $195.42.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/14/2019
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/12/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/12/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/10/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2021BarclaysLower Price TargetOverweight$232.00 ➝ $227.00Medium
i
5/4/2021MizuhoLower Price TargetBuy$228.00 ➝ $216.00N/A
i
5/4/2021Morgan StanleyLower Price TargetOverweight$217.00 ➝ $207.00N/A
i
4/28/2021Morgan StanleyLower Price TargetOverweight$217.00 ➝ $207.00Medium
i
4/28/2021MizuhoLower Price TargetBuy$228.00 ➝ $216.00Medium
i
4/28/2021BarclaysLower Price TargetOverweight$232.00 ➝ $227.00Medium
i
3/22/2021Truist SecuritiesBoost Price TargetBuy$215.00 ➝ $225.00Low
i
3/15/2021Truist SecuritiesBoost Price TargetBuy$215.00 ➝ $225.00High
i
2/12/2021CowenBoost Price TargetOutperform$195.00 ➝ $235.00Low
i
2/4/2021Morgan StanleyBoost Price TargetOverweight$190.00 ➝ $217.00Medium
i
2/1/2021TruistBoost Price Target$200.00 ➝ $215.00Low
i
2/1/2021MizuhoBoost Price TargetBuy$222.00 ➝ $228.00Low
i
2/1/2021BarclaysBoost Price TargetOverweight$190.00 ➝ $232.00Low
i
1/22/2021Bank of AmericaBoost Price TargetBuy$195.00 ➝ $225.00Medium
i
1/19/2021MizuhoUpgradeNeutral ➝ Buy$164.00 ➝ $222.00N/A
i
1/12/2021TruistBoost Price Target$182.00 ➝ $200.00Medium
i
12/16/2020MizuhoBoost Price TargetNeutral$156.00 ➝ $164.00High
i
12/10/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00Medium
i
11/17/2020MizuhoLower Price TargetNeutral$164.00 ➝ $156.00Low
i
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$150.00Low
i
10/28/2020Morgan StanleyLower Price TargetOverweight$176.00 ➝ $170.00Low
i
10/23/2020TruistInitiated CoverageBuy$180.00Medium
i
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$190.00 ➝ $200.00Low
i
9/29/2020Berenberg BankInitiated CoverageHold$144.00Medium
i
9/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$149.55 ➝ $176.00High
i
8/14/2020Morgan StanleyBoost Price TargetEqual Weight$148.00 ➝ $157.00Low
i
6/29/2020MizuhoBoost Price TargetNeutral$155.00 ➝ $164.00Low
i
Rating by Vamil Divan at Mizuho
6/19/2020Bank of AmericaReiterated RatingBuy$180.00Low
i
Rating by Geoff Meacham at Bank of America Co.
6/17/2020JPMorgan Chase & Co.Boost Price TargetOverweight$175.00 ➝ $190.00Low
i
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$182.00High
i
4/24/2020MizuhoBoost Price TargetBuy$148.00 ➝ $155.00Low
i
Rating by Vamil Divan at Mizuho
4/24/2020CfraBoost Price TargetHold$146.00 ➝ $167.00Low
i
4/24/2020Cantor FitzgeraldBoost Price TargetOverweight$156.00 ➝ $185.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
4/20/2020UBS GroupDowngradeBuy ➝ Neutral$157.00 ➝ $158.00High
i
4/19/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
Rating by David Risinger at Morgan Stanley
4/15/2020CowenBoost Price TargetOutperform$145.00 ➝ $160.00Medium
i
4/9/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00Low
i
Rating by David Risinger at Morgan Stanley
4/2/2020MizuhoReiterated RatingHold$148.00Medium
i
Rating by Vamil Divan at Mizuho
4/2/2020Morgan StanleyLower Price TargetOverweight ➝ Equal Weight$150.00 ➝ $148.00High
i
Rating by David Risinger at Morgan Stanley
3/11/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$168.00Medium
i
2/27/2020BarclaysInitiated CoverageOverweightHigh
i
2/18/2020Cantor FitzgeraldReiterated RatingBuy$156.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
2/5/2020MizuhoInitiated CoverageNeutral$148.00Low
i
2/3/2020Cantor FitzgeraldReiterated RatingBuy$156.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
12/30/2019ArgusBoost Price TargetBuy$145.00 ➝ $165.00Low
i
12/18/2019JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $150.00High
i
12/18/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$116.00 ➝ $150.00High
i
12/2/2019Cantor FitzgeraldReiterated RatingBuy$143.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
10/17/2019UBS GroupLower Price TargetBuy$134.00 ➝ $133.00Low
i
10/16/2019Bank of AmericaInitiated CoverageBuy$133.00Low
i
Rating by Jason Gerberry at Bank of America Co.
9/10/2019Bank of AmericaSet Price TargetNeutral$118.00 ➝ $120.00High
i
Rating by Jason Gerberry at Bank of America Co.
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$135.00Low
i
5/1/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $133.00Low
i
4/30/2019Cantor FitzgeraldReiterated RatingBuy$143.00Medium
i
4/23/2019Edward JonesUpgradeHold ➝ Buy$117.49Low
i
4/22/2019BMO Capital MarketsLower Price TargetOutperform$130.00Medium
i
4/14/2019BarclaysReiterated RatingBuy$140.00Low
i
4/11/2019GuggenheimDowngradeBuy ➝ Neutral$125.84Low
i
3/22/2019Credit Suisse GroupSet Price TargetHold$121.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
3/21/2019Bank of AmericaSet Price TargetHold$129.00Low
i
Rating by Jason Gerberry at Bank of America Co.
3/20/2019UBS GroupInitiated CoverageBuy$140.00 ➝ $74.51Low
i
3/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
2/26/2019CitigroupSet Price TargetHold$124.00Medium
i
Rating by Andrew Baum at Citigroup Inc.
2/8/2019UBS GroupLower Price TargetAverage$107.53 ➝ $100.00Low
i
2/4/2019Cantor FitzgeraldReiterated RatingBuyLow
i
Rating by Louise Chen at Cantor Fitzgerald
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$131.00Low
i
1/20/2019BarclaysReiterated RatingBuy$130.00Low
i
12/27/2018ArgusReiterated RatingBuyMedium
i
12/24/2018BMO Capital MarketsBoost Price TargetOutperform$124.00 ➝ $132.00Low
i
12/20/2018Morgan StanleySet Price TargetHold$116.00High
i
Rating by David Risinger at Morgan Stanley
12/19/2018BMO Capital MarketsReiterated RatingBuyLow
i
12/2/2018CitigroupDowngradeBuy ➝ Neutral$113.00Low
i
Rating by Andrew Baum at Citigroup Inc.
11/26/2018CitigroupDowngradeBuy ➝ Neutral$115.00Low
i
Rating by Andrew Baum at Citigroup Inc.
11/7/2018Societe GeneraleSet Price TargetHold$106.00High
i
Rating by Florent Cespedes at Societe Generale
10/31/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralMedium
i
Rating by Vamil Divan at Credit Suisse Group AG
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform$119.00Low
i
10/17/2018Cantor FitzgeraldReiterated RatingBuy$128.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
10/12/2018BarclaysBoost Price TargetOverweight$112.00 ➝ $120.00Low
i
Rating by Geoff Meacham at Barclays PLC
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
i
10/5/2018JPMorgan Chase & Co.Set Price TargetBuy$123.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
10/4/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$107.00 ➝ $130.00High
i
10/3/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$90.00 ➝ $107.00Medium
i
10/1/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$105.00 ➝ $123.00Low
i
9/27/2018Cantor FitzgeraldSet Price TargetBuy$110.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/26/2018JPMorgan Chase & Co.Set Price TargetNot Rated ➝ Overweight$117.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
9/18/2018BarclaysReiterated RatingOverweight$107.00 ➝ $112.00Low
i
Rating by Geoff Meacham at Barclays PLC
9/17/2018Cantor FitzgeraldSet Price TargetBuy$110.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$98.00 ➝ $107.00Medium
i
Rating by Geoff Meacham at Barclays PLC
7/31/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $102.00Low
i
7/31/2018SunTrust BanksReiterated RatingBuy$105.00Low
i
7/25/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$90.00 ➝ $94.00Medium
i
7/25/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Underperform$84.00 ➝ $86.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
7/25/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$80.00 ➝ $90.00High
i
Rating by Alex Arfaei at BMO Capital Markets
7/25/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $110.00High
i
Rating by Louise Chen at Cantor Fitzgerald
7/25/2018Berenberg BankDowngradeBuy ➝ Hold$99.00High
i
7/25/2018The Goldman Sachs GroupSet Price TargetNeutral$100.00High
i
7/24/2018CowenSet Price TargetBuy$105.00High
i
Rating by Steve Scala at Cowen Inc
7/24/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
i
Rating by Louise Chen at Cantor Fitzgerald
7/19/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ $89.43$78.00 ➝ $80.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
7/17/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/17/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$86.00 ➝ $90.00Low
i
7/15/2018Jefferies Financial GroupSet Price TargetBuy$100.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/13/2018Credit Suisse GroupSet Price TargetHold$84.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
7/9/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
6/22/2018DZ BankReiterated RatingBuy ➝ HoldLow
i
6/21/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Underperform$82.00 ➝ $84.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
6/11/2018JPMorgan Chase & Co.Set Price TargetBuy$100.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
6/7/2018Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
i
Rating by L. Chen at Cantor Fitzgerald
5/22/2018BarclaysSet Price TargetBuy$98.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/15/2018Credit Suisse GroupSet Price TargetHold$82.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
5/10/2018BMO Capital MarketsReiterated RatingHold$78.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/25/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$79.00 ➝ $78.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
4/24/2018BMO Capital MarketsReiterated RatingHold$79.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
4/22/2018Credit Suisse GroupSet Price TargetHold$80.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
4/18/2018HC WainwrightReiterated RatingBuyLow
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/13/2018BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$74.00 ➝ $79.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/13/2018Jefferies Financial GroupSet Price TargetBuy$90.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/4/2018BMO Capital MarketsReiterated RatingSell$74.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
3/23/2018Jefferies Financial GroupReiterated RatingBuy$91.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/26/2018Jefferies Financial GroupSet Price TargetBuy$93.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/26/2018JPMorgan Chase & Co.Set Price TargetBuy$105.00Medium
i
Rating by Chris Schott at JPMorgan Chase & Co.
2/2/2018Credit Suisse GroupReiterated RatingHold$80.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
2/1/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$88.00 ➝ $86.00Low
i
2/1/2018BMO Capital MarketsBoost Price TargetUnderperform ➝ Underperform$73.00 ➝ $74.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/22/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform$82.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
1/16/2018Jefferies Financial GroupSet Price TargetBuy$100.00High
i
1/16/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$86.98 ➝ $95.00High
i
1/5/2018ArgusUpgradeHold ➝ Buy$85.52 ➝ $115.00Medium
i
12/13/2017Credit Suisse GroupReiterated RatingHoldMedium
i
Rating by Vamil Divan at Credit Suisse Group AG
12/12/2017BMO Capital MarketsSet Price TargetSell$73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
12/5/2017BMO Capital MarketsSet Price TargetSell$73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
11/21/2017Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $90.00N/A
i
Rating by David Risinger at Morgan Stanley
11/1/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/A
i
10/24/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$92.00 ➝ $93.00N/A
i
Rating by S. Fernandez at SVB Leerink LLC
10/16/2017BMO Capital MarketsSet Price TargetSell$73.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/A
i
10/13/2017BarclaysBoost Price TargetOverweight$90.00 ➝ $98.00N/A
i
10/10/2017BMO Capital MarketsBoost Price TargetUnderperform$71.00 ➝ $73.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/10/2017Credit Suisse GroupDowngradeOutperform ➝ Neutral$84.23 ➝ $88.00N/A
i
10/6/2017Morgan StanleySet Price TargetHold$86.00N/A
i
Rating by David Risinger at Morgan Stanley
10/5/2017The Goldman Sachs GroupReiterated RatingBuy$92.00 ➝ $95.00N/A
i
10/4/2017CowenReiterated RatingBuy$95.00Low
i
Rating by Steve Scala at Cowen Inc
9/28/2017BMO Capital MarketsReiterated RatingSell$71.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
9/15/2017Morgan StanleyReiterated RatingHold$86.00Low
i
Rating by David Risinger at Morgan Stanley
9/11/2017Jefferies Financial GroupReiterated RatingBuy$89.00 ➝ $89.00Low
i
9/8/2017Piper Jaffray CompaniesReiterated RatingOverweight$103.00 ➝ $105.00Low
i
Rating by Richard Purkiss at Piper Jaffray Companies
9/6/2017BMO Capital MarketsReiterated RatingUnderperform$73.00 ➝ $71.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
8/31/2017Jefferies Financial GroupReiterated RatingBuy$89.00Medium
i
8/31/2017Piper Jaffray CompaniesReiterated RatingBuy$103.00Low
i
Rating by Richard Purkiss at Piper Jaffray Companies
8/31/2017SVB LeerinkReiterated RatingHoldLow
i
Rating by S. Fernandez at SVB Leerink LLC
8/24/2017Jefferies Financial GroupReiterated RatingBuy$94.00 ➝ $89.00Low
i
8/16/2017BMO Capital MarketsReiterated RatingSell$73.00High
i
Rating by Alex Arfaei at BMO Capital Markets
8/4/2017Berenberg BankReiterated RatingBuy$98.00Low
i
8/4/2017BMO Capital MarketsReiterated RatingSell$73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/27/2017Berenberg BankReiterated RatingBuy$100.00Low
i
7/26/2017UBS GroupDowngradeHold$85.00Medium
i
Rating by Marc Goodman at UBS Group AG
7/26/2017OppenheimerDowngradeOutperform ➝ Market Perform$90.00 ➝ $90.00Low
i
7/26/2017BMO Capital MarketsReiterated RatingUnderperform$73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/26/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$93.00 ➝ $90.00Low
i
Rating by S. Fernandez at SVB Leerink LLC
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$90.00 ➝ $91.00Low
i
7/13/2017Jefferies Financial GroupReiterated RatingBuy$93.00 ➝ $96.00Low
i
7/4/2017CitigroupReiterated RatingBuy$100.00Low
i
Rating by Andrew Baum at Citigroup Inc.
7/4/2017BarclaysBoost Price TargetOverweight$85.00 ➝ $90.00Low
i
Rating by Paul Choi at Barclays PLC
6/22/2017Jefferies Financial GroupReiterated RatingBuy$93.00Low
i
6/5/2017Jefferies Financial GroupReiterated RatingBuy$92.00Low
i
5/30/2017Jefferies Financial GroupReiterated RatingBuyLow
i
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00Medium
i
5/16/2017The Goldman Sachs GroupReiterated RatingConviction-Buy ➝ Buy$92.00High
i
4/29/2017BMO Capital MarketsReiterated RatingUnderperform$71.00 ➝ $73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/29/2017Jefferies Financial GroupReiterated RatingBuy$94.00 ➝ $92.00Low
i
4/27/2017ArgusDowngradeBuy ➝ Hold$64.18 ➝ $81.00Low
i
4/25/2017BMO Capital MarketsSet Price TargetSell$71.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/19/2017CitigroupBoost Price TargetBuy$92.00 ➝ $100.00Low
i
Rating by Andrew Baum at Citigroup Inc.
4/19/2017Credit Suisse GroupReiterated RatingOutperform$87.00Low
i
4/17/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00Medium
i
Rating by Richard Purkiss at Piper Jaffray Companies
4/17/2017CowenBoost Price TargetOutperform$85.00 ➝ $95.00Medium
i
4/17/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$82.00High
i
Rating by David Risinger at Morgan Stanley
4/17/2017BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$73.00 ➝ $71.00High
i
Rating by Alex Arfaei at BMO Capital Markets
4/10/2017Jefferies Financial GroupReiterated RatingBuy$97.00Low
i
4/7/2017BarclaysBoost Price TargetOverweight$85.00 ➝ $90.00Low
i
4/6/2017CitigroupReiterated RatingBuy$100.00Low
i
Rating by Andrew Baum at Citigroup Inc.
3/21/2017Credit Suisse GroupReiterated RatingBuyLow
i
3/20/2017SVB LeerinkReiterated RatingOutperformLow
i
3/20/2017UBS GroupBoost Price TargetNeutral ➝ Neutral$70.00 ➝ $85.00N/A
i
3/11/2017Jefferies Financial GroupReiterated RatingBuy$95.00 ➝ $97.00N/A
i
2/17/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
2/1/2017BarclaysBoost Price TargetBuy$80.00 ➝ $85.00N/A
i
2/1/2017BMO Capital MarketsReiterated RatingMarket Perform$70.00 ➝ $73.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
1/20/2017Jefferies Financial GroupBoost Price TargetBuy$90.00 ➝ $93.00N/A
i
1/19/2017CitigroupSet Price TargetBuy$100.00N/A
i
Rating by Andrew Baum at Citigroup Inc.
1/18/2017The Goldman Sachs GroupReiterated RatingConviction-Buy$92.00N/A
i
1/18/2017Credit Suisse GroupReiterated RatingOutperform$87.00N/A
i
12/21/2016The Goldman Sachs GroupReiterated RatingBuy$82.00 ➝ $85.00N/A
i
12/19/2016Credit Suisse GroupReiterated RatingFocus List$87.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
12/16/2016Morgan StanleyUpgradeEqual Weight ➝ Overweight$73.00 ➝ $82.00N/A
i
Rating by David Risinger at Morgan Stanley
12/15/2016The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyN/A
i
12/14/2016BMO Capital MarketsReiterated RatingHold$64.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/A
i
11/26/2016SVB LeerinkReiterated RatingOutperform$102.00 ➝ $92.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
11/26/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/25/2016Atlantic SecuritiesDowngradeOverweight ➝ NeutralN/A
i
11/24/2016JPMorgan Chase & Co.Set Price TargetBuy$85.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
11/24/2016Morgan StanleySet Price TargetHold$73.00N/A
i
Rating by David Risinger at Morgan Stanley
11/23/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$91.00 ➝ $64.00N/A
i
11/8/2016CitigroupReiterated RatingBuyN/A
i
10/28/2016Jefferies Financial GroupReiterated RatingBuy$105.00 ➝ $100.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/A
i
10/26/2016The Goldman Sachs GroupReiterated RatingBuy$95.00N/A
i
10/9/2016SVB LeerinkReiterated RatingBuy$103.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
10/3/2016BMO Capital MarketsReiterated RatingBuy$94.00N/A
i
9/27/2016BMO Capital MarketsReiterated RatingOutperform$94.00N/A
i
9/27/2016The Goldman Sachs GroupUpgradeNeutral ➝ Buy$89.00 ➝ $95.00N/A
i
9/20/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by gregg gilbert at Deutsche Bank Aktiengesellschaft
9/14/2016Jefferies Financial GroupReiterated RatingBuy$105.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/8/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$92.00 ➝ $95.00N/A
i
8/13/2016SVB LeerinkReiterated RatingOutperform$105.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
8/3/2016CitigroupReiterated RatingBuyN/A
i
8/2/2016ArgusBoost Price TargetBuy$90.00 ➝ $95.00N/A
i
7/27/2016BMO Capital MarketsReiterated RatingBuy$94.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
7/14/2016Jefferies Financial GroupBoost Price TargetBuy$100.00 ➝ $105.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/6/2016Credit Suisse GroupReiterated RatingBuy$91.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
6/28/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Vamil Divan at Credit Suisse Group AG
6/26/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
6/15/2016SunTrust BanksReiterated RatingBuyN/A
i
Rating by John Boris at SunTrust Banks, Inc.
6/4/2016Morgan StanleyReiterated RatingHold$88.00N/A
i
Rating by David Risinger at Morgan Stanley
5/26/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Vamil Divan at Credit Suisse Group AG
5/25/2016UBS GroupReiterated RatingHold$82.00N/A
i
5/13/2016Jefferies Financial GroupReiterated RatingBuy$100.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
(Data available from 5/8/2016 forward)
Eli Lilly and logo
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $195.42
$193.90
$196.27

50 Day Range

MA: $185.56
$180.17
$193.89

52 Week Range

Now: $195.42
$129.21
$218.00

Volume

2,525,643 shs

Average Volume

4,044,938 shs

Market Capitalization

$187.41 billion

P/E Ratio

31.93

Dividend Yield

1.75%

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, Cowen Inc, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Sanford C. Bernstein, Truist, Truist Securities, and Wolfe Research.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and?

12 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $200.75, suggesting a possible upside of 2.7%. Cowen Inc has the highest price target set, predicting LLY will reach $235.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $144.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and?

Eli Lilly and currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.

What other companies compete with Eli Lilly and?

How do I contact Eli Lilly and's investor relations team?

Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is 317-276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com.